---
figid: PMC6542018__13046_2019_1236_Fig1_HTML
figlink: /pmc/articles/PMC6542018/figure/Fig1/
number: Fig. 1
caption: Estrogen receptor (ER) activity in breast cancer - canonical (classical;
  ligand-mediated) and non-canonical (alternative; ligand-independent) pathways of
  ER activation. a In the canonical model, estrogen binds to ER, which results in
  receptor dimerization, subsequent translocation to the nucleus and binding to specific
  genomic sequences i.e. estrogen responsive elements. Activated ER interacts with
  co-regulators, that modulate target genes expression. This is followed by ER ubiquitination
  and degradation via a 26-proteasome complex. In the non-canonical pathways (b-d),
  activity of ER is regulated in a ligand-independent manner by stimuli (FGFs) from
  the tumour microenvironment (TME). Binding of FGFs to their cognate receptors, FGFRs,
  induces FGFRS-triggered signalling, which targets ER. b FGF3/FGFR1-triggered signalling
  leads to induction of ER-FGFR1 complex formation, which binds to unknown genomic
  sequences and regulates expression of ER-dependent genes. c FGF10/FGFR2-activated
  pathway strengthens the interaction between ER and two transcription factors (NFIB
  and YBX1), which upon binding to ER-FOXA1 suppress ER-dependent gene expression,
  d FGF7/FGFR2-dependent activation of PI3K/AKT induces ER phosphorylation, enhanced
  ER transcriptional activity and increased ER degradation. E – estrogen; ER – estrogen
  receptor; ERE – estrogen responsive element; Ub - ubiquitin
pmcid: PMC6542018
papertitle: FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors
  – implications for therapy of luminal breast cancer.
reftext: Dominika Piasecka, et al. J Exp Clin Cancer Res. 2019;38:230.
pmc_ranked_result_index: '29191'
pathway_score: 0.9454359
filename: 13046_2019_1236_Fig1_HTML.jpg
figtitle: Estrogen receptor (ER) activity in breast cancer - canonical (classical;
  ligand-mediated) and non-canonical (alternative; ligand-independent) pathways of
  ER activation
year: '2019'
organisms: Homo sapiens
ndex: 069731b3-deff-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6542018__13046_2019_1236_Fig1_HTML.html
  '@type': Dataset
  description: Estrogen receptor (ER) activity in breast cancer - canonical (classical;
    ligand-mediated) and non-canonical (alternative; ligand-independent) pathways
    of ER activation. a In the canonical model, estrogen binds to ER, which results
    in receptor dimerization, subsequent translocation to the nucleus and binding
    to specific genomic sequences i.e. estrogen responsive elements. Activated ER
    interacts with co-regulators, that modulate target genes expression. This is followed
    by ER ubiquitination and degradation via a 26-proteasome complex. In the non-canonical
    pathways (b-d), activity of ER is regulated in a ligand-independent manner by
    stimuli (FGFs) from the tumour microenvironment (TME). Binding of FGFs to their
    cognate receptors, FGFRs, induces FGFRS-triggered signalling, which targets ER.
    b FGF3/FGFR1-triggered signalling leads to induction of ER-FGFR1 complex formation,
    which binds to unknown genomic sequences and regulates expression of ER-dependent
    genes. c FGF10/FGFR2-activated pathway strengthens the interaction between ER
    and two transcription factors (NFIB and YBX1), which upon binding to ER-FOXA1
    suppress ER-dependent gene expression, d FGF7/FGFR2-dependent activation of PI3K/AKT
    induces ER phosphorylation, enhanced ER transcriptional activity and increased
    ER degradation. E – estrogen; ER – estrogen receptor; ERE – estrogen responsive
    element; Ub - ubiquitin
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - AKT3
  - FGFR1
  - FGFR2
  - FOXA1
  - YBX1
  - PIK3R4
  - NFIB
  - PIK3R6
  - PIK3R5
  - FGF3
  - PIK3CA
  - AKT2
  - FGF10
  - FGF7
  - PIK3CG
  - PIK3R3
  - PIK3CD
  - PIK3CB
  - Ser
  - Cancer
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: FGFR1
  symbol: FGFR1
  source: hgnc_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR2
  symbol: FGFR2
  source: hgnc_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: FOXA1
  symbol: FOXA1
  source: hgnc_symbol
  hgnc_symbol: FOXA1
  entrez: '3169'
- word: YBX1
  symbol: YBX1
  source: hgnc_symbol
  hgnc_symbol: YBX1
  entrez: '4904'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: NFIB
  symbol: NFIB
  source: hgnc_symbol
  hgnc_symbol: NFIB
  entrez: '4781'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: FGF3
  symbol: FGF3
  source: hgnc_symbol
  hgnc_symbol: FGF3
  entrez: '2248'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: FGF10
  symbol: FGF10
  source: hgnc_symbol
  hgnc_symbol: FGF10
  entrez: '2255'
- word: FGF7
  symbol: FGF7
  source: hgnc_symbol
  hgnc_symbol: FGF7
  entrez: '2252'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: Ser
  source: MESH
  identifier: C530429
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
